Mid-regional pro-adrenomedullin as a supplementary tool to clinical parameters in cases of suspicion of infection in the emergency department.
Expert Rev Mol Diagn
; 21(4): 397-404, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-1142579
ABSTRACT
INTRODUCTION:
Mid-regional proadrenomedullin (MR-proADM), a novel biomarker, has recently gained interest particularly with regards to its potential in assisting clinicians' decision making in patients with suspicion of infection in the emergency department (ED). A group of international experts, with research and experience in MR-proADM applications, produced this review based on their own experience and the currently available literature. AREAS COVERED The review provides evidence related to MR-proADM as a triaging tool in avoiding unnecessary admissions to hospital and/or inadequate discharge, and identifying patients most at risk of deterioration. It also covers the use of MR-proADM in the context of COVID-19. Moreover, the authors provide a proposal on how to incorporate MR-proADM into patients' clinical pathways in an ED setting. EXPERT OPINION The data we have so far on the application of MR-proADM in the ED is promising. Incorporating it into clinical scoring systems may aid the clinician's decision making and recognizing the 'ill looking well' and the 'well looking ill' sooner. However there are still many gaps in our knowledge especially during the ongoing COVID-19 waves. There is also a need for cost-effectiveness analysis studies especially in the era of increasing cost pressures on health systems globally.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Protein Precursors
/
Biomarkers
/
Adrenomedullin
/
COVID-19
/
Infections
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Expert Rev Mol Diagn
Journal subject:
Molecular Biology
Year:
2021
Document Type:
Article
Affiliation country:
14737159.2021.1902312
Similar
MEDLINE
...
LILACS
LIS